PIK3CA and MAP3K1 alterations imply luminal A status and are associated with clinical benefit from pan-PI3K inhibitor buparlisib and letrozole in ER+ metastatic breast cancer

Clinical trials have demonstrated the efficacy of combining phosphoinositide 3-kinase (PI3K) inhibitors with endocrine therapies in hormone therapy-refractory breast cancer. However, biomarkers of PI3K pathway dependence in ER+ breast cancer have not been fully established. Hotspot mutations in the...

Descripción completa

Detalles Bibliográficos
Autores principales: Nixon, Mellissa J., Formisano, Luigi, Mayer, Ingrid A., Estrada, M. Valeria, González-Ericsson, Paula I., Isakoff, Steven J., Forero-Torres, Andrés, Won, Helen, Sanders, Melinda E., Solit, David B., Berger, Michael F., Cantley, Lewis C., Winer, Eric P., Arteaga, Carlos L., Balko, Justin M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6757060/
https://www.ncbi.nlm.nih.gov/pubmed/31552290
http://dx.doi.org/10.1038/s41523-019-0126-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6757060/
https://www.ncbi.nlm.nih.gov/pubmed/31552290
http://dx.doi.org/10.1038/s41523-019-0126-6

Ejemplares similares